Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor

ACS Chemical Neuroscience

Volumn 8, Issue 6, 2017, Pages 1188-1203

  Laprairie, Robert B ^a   Kulkarni, Pushkar M ^b   Deschamps, Jeffrey R ^c   Kelly, Melanie E M ^a   Janero, David R ^b   Cascio, Maria G ^d   Stevenson, Lesley A ^d   Pertwee, Roger G ^d   Kenakin, Terrence P ^e   Denovan Wright, Eileen M ^a   Thakur, Ganesh A ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b NORTHEASTERN UNIVERSITY   (United States)

^c NAVAL RESEARCH LABORATORY   (United States)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

7 transmembrane receptor; Allosteric regulation; cannabinoid; cellular signaling; central nervous system; G protein coupled receptor; ligand bias; molecular pharmacology; probe dependence; receptor activation; therapeutics discovery

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; GAT 211; GAT 228; GAT 229; UNCLASSIFIED DRUG; CANNABINOID RECEPTOR AGONIST;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BRAIN MEMBRANE; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENANTIOMER; EX VIVO STUDY; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRINSIC ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VAS DEFERENS; AGONISTS; ALLOSTERIC SITE; ANIMAL; CHEMISTRY; DRUG EFFECTS; ISOMERISM; SYNTHESIS;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; CANNABINOID RECEPTOR AGONISTS; HEK293 CELLS; HUMANS; ISOMERISM; MICE; RECEPTOR, CANNABINOID, CB1;

EID: 85021100824     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/acschemneuro.6b00310     Document Type: Article

References (67)

1. Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., Mechoulam, R., and Ross, R. A. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2) Pharmacol. Rev. 62, 588-631 10.1124/pr.110.003004
2. Pertwee, R. G. (2015) Endocannabinoids and Their Pharmacological Actions Handb. Exp. Pharmacol. 231, 1-37 10.1007/978-3-319-20825-1-1
3. Pertwee, R. G. (2008) Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond Addict Biol. 13, 147-159 10.1111/j.1369-1600.2008.00108.x
4. Pacher, P., Batkai, S., and Kunos, G. (2006) The endocannabinoid system as an emerging target of pharmacotherapy Pharmacol. Rev. 58, 389-462 10.1124/pr.58.3.2
5. Pacher, P. and Kunos, G. (2013) Modulating the endocannabinoid system in human health and disease - successes and failures FEBS J. 280, 1918-1943 10.1111/febs.12260
6. Di Marzo, V. (2008) Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug Discovery 7, 438-455 10.1038/nrd2553
7. Vemuri, V. K., Janero, D. R., and Makriyannis, A. (2008) Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome Physiol. Behav. 93, 671-686 10.1016/j.physbeh.2007.11.012
8. Thakur, G. A., Tichkule, R., Bajaj, S., and Makriyannis, A. (2009) Latest advances in cannabinoid receptor agonists Expert Opin. Ther. Pat. 19, 1647-1673 10.1517/13543770903436505
9. Janero, D. R. (2012) Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists Expert Opin. Emerging Drugs 17, 17-29 10.1517/14728214.2012.660916
10. Aizpurua-Olaizola, O., Elezgarai, I., Rico-Barrio, I., Zarandona, I., Etxebarria, N., and Usobiaga, A. (2017) Targeting the endocannabinoid system: future therapeutic strategies Drug Discovery Today 22, 105 10.1016/j.drudis.2016.08.005
11. Dixon, D. D., Sethumadhavan, D., Benneche, T., Banaag, A. R., Tius, M. A., Thakur, G. A., Bowman, A., Wood, J. T., and Makriyannis, A. (2010) Heteroadamantyl cannabinoids J. Med. Chem. 53, 5656-5666 10.1021/jm100390h
12. Thakur, G. A., Palmer, S. L., Harrington, P. E., Stergiades, I. A., Tius, M. A., and Makriyannis, A. (2002) Enantiomeric resolution of a novel chiral cannabinoid receptor ligand J. Biochem. Biophys. Methods 54, 415-422 10.1016/S0165-022X(02)00144-6
13. Pertwee, R. G. (2012) Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities Philos. Trans. R. Soc., B 367, 3353-3363 10.1098/rstb.2011.0381
14. Ross, R. A. (2007) Allosterism and cannabinoid CB(1) receptors: the shape of things to come Trends Pharmacol. Sci. 28, 567-572 10.1016/j.tips.2007.10.006
15. Morales, P., Goya, P., Jagerovic, N., and Hernandez-Folgado, L. (2016) Allosteric Modulators of the CB1 Cannabinoid Receptor: A Structural Update Review Cannabis and Cannabinoid Research 1, 22-30 10.1089/can.2015.0005
16. Busquets Garcia, A., Soria-Gomez, E., Bellocchio, L., and Marsicano, G. (2016) Cannabinoid receptor type-1: breaking the dogmas F1000Research 5, 990 10.12688/f1000research.8245.1
17. Abood, M. E. (2016) Allosteric Modulators: A Side Door J. Med. Chem. 59, 42-43 10.1021/acs.jmedchem.5b01824
18. Lindsley, C. W., Emmitte, K. A., Hopkins, C. R., Bridges, T. M., Gregory, K. J., Niswender, C. M., and Conn, P. J. (2016) Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors Chem. Rev. 116, 6707-6741 10.1021/acs.chemrev.5b00656
19. Conn, P. J., Lindsley, C. W., Meiler, J., and Niswender, C. M. (2014) Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders Nat. Rev. Drug Discovery 13, 692-708 10.1038/nrd4308
20. Gentry, P. R., Sexton, P. M., and Christopoulos, A. (2015) Novel Allosteric Modulators of G Protein-coupled Receptors J. Biol. Chem. 290, 19478-19488 10.1074/jbc.R115.662759
21. Wootten, D., Christopoulos, A., and Sexton, P. M. (2013) Emerging paradigms in GPCR allostery: implications for drug discovery Nat. Rev. Drug Discovery 12, 630-644 10.1038/nrd4052
22. Price, M. R., Baillie, G. L., Thomas, A., Stevenson, L. A., Easson, M., Goodwin, R., McLean, A., McIntosh, L., Goodwin, G., Walker, G., Westwood, P., Marrs, J., Thomson, F., Cowley, P., Christopoulos, A., Pertwee, R. G., and Ross, R. A. (2005) Allosteric modulation of the cannabinoid CB1 receptor Molecular pharmacology 68, 1484-1495 10.1124/mol.105.016162
23. Horswill, J. G., Bali, U., Shaaban, S., Keily, J. F., Jeevaratnam, P., Babbs, A. J., Reynet, C., and Wong Kai In, P. (2007) PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats British journal of pharmacology 152, 805-814 10.1038/sj.bjp.0707347
24. Wang, X., Horswill, J. G., Whalley, B. J., and Stephens, G. J. (2011) Effects of the allosteric antagonist 1-(4-chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum Mol. Pharmacol. 79, 758-767 10.1124/mol.110.068197
25. Baillie, G. L., Horswill, J. G., Anavi-Goffer, S., Reggio, P. H., Bolognini, D., Abood, M. E., McAllister, S., Strange, P. G., Stephens, G. J., Pertwee, R. G., and Ross, R. A. (2013) CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity Mol. Pharmacol. 83, 322-338 10.1124/mol.112.080879
26. Cawston, E. E., Connor, M., Di Marzo, V., Silvestri, R., and Glass, M. (2015) Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signaling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors J. Med. Chem. 58, 5979 10.1021/acs.jmedchem.5b00579
27. Khajehali, E., Malone, D. T., Glass, M., Sexton, P. M., Christopoulos, A., and Leach, K. (2015) Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor Mol. Pharmacol. 88, 368-379 10.1124/mol.115.099192
28. Gamage, T. F., Ignatowska-Jankowska, B. M., Wiley, J. L., Abdelrahman, M., Trembleau, L., Greig, I. R., Thakur, G. A., Tichkule, R., Poklis, J., Ross, R. A., Pertwee, R. G., and Lichtman, A. H. (2014) In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569 Behav. Pharmacol. 25, 182-185 10.1097/FBP.0000000000000027
29. Shore, D. M., Baillie, G. L., Hurst, D. H., Navas, F., 3rd, Seltzman, H. H., Marcu, J. P., Abood, M. E., Ross, R. A., and Reggio, P. H. (2014) Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling J. Biol. Chem. 289, 5828-5845 10.1074/jbc.M113.478495
30. Laprairie, R. B., Kulkarni, A. R., Kulkarni, P. M., Hurst, D. P., Lynch, D., Reggio, P. H., Janero, D. R., Pertwee, R. G., Stevenson, L. A., Kelly, M. E., Denovan-Wright, E. M., and Thakur, G. A. (2016) Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe ACS Chem. Neurosci. 7, 776-798 10.1021/acschemneuro.6b00041
31. Kulkarni, P. M., Kulkarni, A. R., Korde, A., Tichkule, R. B., Laprairie, R. B., Denovan-Wright, E. M., Zhou, H., Janero, D. R., Zvonok, N., Makriyannis, A., Cascio, M. G., Pertwee, R. G., and Thakur, G. A. (2016) Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s) J. Med. Chem. 59, 44-60 10.1021/acs.jmedchem.5b01303
32. Priestley, R. S., Nickolls, S. A., Alexander, S. P., and Kendall, D. A. (2015) A potential role for cannabinoid receptors in the therapeutic action of fenofibrate FASEB J. 29, 1446-1455 10.1096/fj.14-263053
33. Navarro, H. A., Howard, J. L., Pollard, G. T., and Carroll, F. I. (2009) Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter Br. J. Pharmacol. 156, 1178-1184 10.1111/j.1476-5381.2009.00124.x
34. Ignatowska-Jankowska, B. M., Baillie, G. L., Kinsey, S., Crowe, M., Ghosh, S., Owens, R. A., Damaj, I. M., Poklis, J., Wiley, J. L., Zanda, M., Zanato, C., Greig, I. R., Lichtman, A. H., and Ross, R. A. (2015) A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects Neuropsychopharmacology 40, 2948-2959 10.1038/npp.2015.148
35. Laprairie, R. B., Bagher, A. M., Kelly, M. E., and Denovan-Wright, E. M. (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor Br. J. Pharmacol. 172, 4790-4805 10.1111/bph.13250
36. Pamplona, F. A., Ferreira, J., Menezes de Lima, O., Jr., Duarte, F. S., Bento, A. F., Forner, S., Villarinho, J. G., Bellocchio, L., Wotjak, C. T., Lerner, R., Monory, K., Lutz, B., Canetti, C., Matias, I., Calixto, J. B., Marsicano, G., Guimaraes, M. Z., and Takahashi, R. N. (2012) Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor Proc. Natl. Acad. Sci. U. S. A. 109, 21134-21139 10.1073/pnas.1202906109
37. Vallee, M., Vitiello, S., Bellocchio, L., Hebert-Chatelain, E., Monlezun, S., Martin-Garcia, E., Kasanetz, F., Baillie, G. L., Panin, F., Cathala, A., Roullot-Lacarriere, V., Fabre, S., Hurst, D. P., Lynch, D. L., Shore, D. M., Deroche-Gamonet, V., Spampinato, U., Revest, J. M., Maldonado, R., Reggio, P. H., Ross, R. A., Marsicano, G., and Piazza, P. V. (2014) Pregnenolone can protect the brain from cannabis intoxication Science 343, 94-98 10.1126/science.1243985
38. Bauer, M., Chicca, A., Tamborrini, M., Eisen, D., Lerner, R., Lutz, B., Poetz, O., Pluschke, G., and Gertsch, J. (2012) Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors J. Biol. Chem. 287, 36944-36967 10.1074/jbc.M112.382481
39. van der Westhuizen, E. T., Valant, C., Sexton, P. M., and Christopoulos, A. (2015) Endogenous allosteric modulators of G protein-coupled receptors J. Pharmacol. Exp. Ther. 353, 246-260 10.1124/jpet.114.221606
40. Janero, D. R. and Thakur, G. A. (2016) Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target Expert Opin. Drug Discovery 11, 1223-1237 10.1080/17460441.2016.1245289
41. Thakur, G. A., Kulkarni, A. R., Deschamps, J. R., and Papke, R. L. (2013) Expeditious synthesis, enantiomeric resolution, and enantiomer functional characterization of (4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide (4BP-TQS): an allosteric agonist-positive allosteric modulator of alpha7 nicotinic acetylcholine receptors J. Med. Chem. 56, 8943-8947 10.1021/jm401267t
42. Bagdas, D., Wilkerson, J. L., Kulkarni, A., Toma, W., AlSharari, S., Gul, Z., Lichtman, A. H., Papke, R. L., Thakur, G. A., and Damaj, M. I. (2016) The alpha7 nicotinic receptor dual allosteric agonist and positive allosteric modulator GAT107 reverses nociception in mouse models of inflammatory and neuropathic pain Br. J. Pharmacol. 173, 2506-2520 10.1111/bph.13528
43. Kulkarni, P. M., Ranade, A., Garai, S., and Thakur, G. A. (2017) Microwave-accelerated conjugate addition of 2-arylindoles to substituted β-nitrostyrenes in the presence of ammonium trifluoroacetate: an efficient approach for the synthesis of a novel class of CB1 cannabinoid receptor allosteric modulators J. Heterocycl. Chem. 10.1002/jhet.2861
44. Kulkarni, A. R. and Thakur, G. A. (2013) Microwave-assisted Expeditious and Efficient Synthesis of Cyclopentene Ring-fused Tetrahydroquinoline Derivatives Using Three-component Povarov Reaction Tetrahedron Lett. 54, 6592 10.1016/j.tetlet.2013.09.107
45. Kulkarni, A. R., Garai, S., and Thakur, G. A. (2017) Scalable, One-Pot, Microwave-Accelerated Tandem Synthesis of Unsymmetrical Urea Derivatives J. Org. Chem. 82, 992 10.1021/acs.joc.6b02521
46. Pertwee, R. G., Ross, R. A., Craib, S. J., and Thomas, A. (2002) (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens Eur. J. Pharmacol. 456, 99-106 10.1016/S0014-2999(02)02624-9
47. Stockton, J. M., Birdsall, N. J., Burgen, A. S., and Hulme, E. C. (1983) Modification of the binding properties of muscarinic receptors by gallamine Mol. Pharmacol. 23, 551-557
48. Ehlert, F. J. (1988) Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods Mol. Pharmacol. 33, 187-194
49. Black, J. W. and Leff, P. (1983) Operational models of pharmacological agonism Proc. R. Soc. London, Ser. B 220, 141-162 10.1098/rspb.1983.0093
50. Kenakin, T. (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism Nat. Rev. Drug Discovery 4, 919-927 10.1038/nrd1875
51. Kenakin, T. (2015) Gaddum Memorial Lecture 2014: receptors as an evolving concept: from switches to biased microprocessors Br. J. Pharmacol. 172, 4238-4253 10.1111/bph.13217
52. Barnett-Norris, J., Hurst, D. P., Lynch, D. L., Guarnieri, F., Makriyannis, A., and Reggio, P. H. (2002) Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor J. Med. Chem. 45, 3649-3659 10.1021/jm0200761
53. Pertwee, R. G. (2005) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors Life Sci. 76, 1307-1324 10.1016/j.lfs.2004.10.025
54. Christopoulos, A. and Kenakin, T. (2002) G protein-coupled receptor allosterism and complexing Pharmacol. Rev. 54, 323-374 10.1124/pr.54.2.323
55. Sugiura, T., Kodaka, T., Nakane, S., Miyashita, T., Kondo, S., Suhara, Y., Takayama, H., Waku, K., Seki, C., Baba, N., and Ishima, Y. (1999) Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds J. Biol. Chem. 274, 2794-2801 10.1074/jbc.274.5.2794
56. Schlosburg, J. E., Blankman, J. L., Long, J. Z., Nomura, D. K., Pan, B., Kinsey, S. G., Nguyen, P. T., Ramesh, D., Booker, L., Burston, J. J., Thomas, E. A., Selley, D. E., Sim-Selley, L. J., Liu, Q. S., Lichtman, A. H., and Cravatt, B. F. (2010) Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system Nat. Neurosci. 13, 1113-1119 10.1038/nn.2616
57. Schlosburg, J. E., Kinsey, S. G., Ignatowska-Jankowska, B., Ramesh, D., Abdullah, R. A., Tao, Q., Booker, L., Long, J. Z., Selley, D. E., Cravatt, B. F., and Lichtman, A. H. (2014) Prolonged monoacylglycerol lipase blockade causes equivalent cannabinoid receptor type 1 receptor-mediated adaptations in fatty acid amide hydrolase wild-type and knockout mice J. Pharmacol. Exp. Ther. 350, 196-204 10.1124/jpet.114.212753
58. Fowler, C. J. (2015) The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review Handb. Exp. Pharmacol. 231, 95-128 10.1007/978-3-319-20825-1-4
59. Bagher, A. M., Laprairie, R. B., Kelly, M. E., and Denovan-Wright, E. M. (2013) Co-expression of the human cannabinoid receptor coding region splice variants (hCB(1)) affects the function of hCB(1) receptor complexes Eur. J. Pharmacol. 721, 341-354 10.1016/j.ejphar.2013.09.002
60. Laprairie, R. B., Bagher, A. M., Kelly, M. E., Dupre, D. J., and Denovan-Wright, E. M. (2014) Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons J. Biol. Chem. 289, 24845-24862 10.1074/jbc.M114.557025
61. Thomas, A., Ross, R. A., Saha, B., Mahadevan, A., Razdan, R. K., and Pertwee, R. G. (2004) 6″-Azidohex-2″-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist Eur. J. Pharmacol. 487, 213-221 10.1016/j.ejphar.2004.01.023
62. Pertwee, R. G., Fernando, S. R., Griffin, G., Ryan, W., Razdan, R. K., Compton, D. R., and Martin, B. R. (1996) Agonist-antagonist characterization of 6′-cyanohex-2′-yne-delta 8-tetrahydrocannabinol in two isolated tissue preparations Eur. J. Pharmacol. 315, 195-201 10.1016/S0014-2999(96)00631-0
63. Leach, K., Sexton, P. M., and Christopoulos, A. (2011) Quantification of allosteric interactions at G protein-coupled receptors using radioligand binding assays Curr. Protoc. Pharmacol. 22 10.1002/0471141755.ph0122s52
64. Ross, R. A., Gibson, T. M., Stevenson, L. A., Saha, B., Crocker, P., Razdan, R. K., and Pertwee, R. G. (1999) Structural determinants of the partial agonist-inverse agonist properties of 6′-azidohex-2′-yne-delta8-tetrahydrocannabinol at cannabinoid receptors Br. J. Pharmacol. 128, 735-743 10.1038/sj.bjp.0702836
65. James, J. R., Oliveira, M. I., Carmo, A. M., Iaboni, A., and Davis, S. J. (2006) A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer Nat. Methods 3, 1001-1006 10.1038/nmeth978
66. Black, J. W., Leff, P., Shankley, N. P., and Wood, J. (1985) An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation Br. J. Pharmacol. 84, 561-571 10.1111/j.1476-5381.1985.tb12941.x
67. Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A., and Novick, S. (2012) A simple method for quantifying functional selectivity and agonist bias ACS Chem. Neurosci. 3, 193-203 10.1021/cn200111m